Delving into the Latest Updates on CaroGen Corp. with Synapse

概览

疾病领域	数量

肿瘤	2
内分泌与代谢疾病	1
感染	1

排名前五的药物类型	数量

疫苗	2
溶瘤病毒	1

排名前五的靶点	数量

PDL1(程序性死亡配体1)	1

关联

6

项与 CaroGen Corp. 相关的药物

VLV IL 12p35

靶点-

作用机制

细胞死亡刺激剂

在研机构

University of Connecticut

原研机构

CaroGen Corp.

在研适应症

结直肠癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

CARG-2020

靶点

PDL1

作用机制

PDL1抑制剂

在研机构

CaroGen Corp. [+1]

原研机构

CaroGen Corp.

在研适应症

乳腺癌 [+4]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

VLV based Vaccine(CaroGen)

靶点-

作用机制-

在研机构

Brown University [+1]

原研机构

CaroGen Corp.

在研适应症

乳腺癌 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 CaroGen Corp. 相关的临床结果

登录后查看更多信息

0 项与 CaroGen Corp. 相关的专利（医药）

登录后查看更多信息

10

项与 CaroGen Corp. 相关的文献（医药）

2024-01-01·Acta Pharmaceutica Sinica B

Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence

Article

作者: Wang, Isabella China ; Pitmon, Elise ; Meehan, Eileen Victoria ; Yarovinsky, Timur Olegovich ; Nakaar, Valerian ; Chen, Ju ; Ye, Xiaoyang ; Madina, Bhaskara Reddy ; Almassian, Bijan ; Ma, Xian-Yong ; Krady, Marie Marthe ; Ahmadi, Elham ; Wang, Kepeng

Targeting multiple immune mechanisms may overcome therapy resistance and further improve cancer immunotherapy for humans. Here, we describe the application of virus-like vesicles (VLV) for delivery of three immunomodulators alone and in combination, as a promising approach for cancer immunotherapy. VLV vectors were designed to deliver single chain interleukin (IL)-12, short-hairpin RNA (shRNA) targeting programmed death ligand 1 (PD-L1), and a dominant-negative form of IL-17 receptor A (dn-IL17RA) as a single payload or as a combination payload. Intralesional delivery of the VLV vector expressing IL-12 alone, as well as the trivalent vector (designated CARG-2020) eradicated large established tumors. However, only CARG-2020 prevented tumor recurrence and provided long-term survival benefit to the tumor-bearing mice, indicating a benefit of the combined immunomodulation. The abscopal effects of CARG-2020 on the non-injected contralateral tumors, as well as protection from the tumor cell re-challenge, suggest immune-mediated mechanism of protection and establishment of immunological memory. Mechanistically, CARG-2020 potently activates Th1 immune mechanisms and inhibits expression of genes related to T cell exhaustion and cancer-promoting inflammation. The ability of CARG-2020 to prevent tumor recurrence and to provide survival benefit makes it a promising candidate for its development for human cancer immunotherapy.

2023-01-01·International journal of nanomedicine

How Magnetic Composites are Effective Anticancer Therapeutics? A Comprehensive Review of the Literature.

Review

作者: Kuča, Kamil ; Shameli, Kamyar ; Jahangirian, Hossein ; Mohamad Sukri, Siti Nur Amalina ; Yusefi, Mostafa ; Afsah-Hejri, Leili ; Teow, Sin-Yeang

Chemotherapy is the most prominent route in cancer therapy for prolonging the lifespan of cancer patients. However, its non-target specificity and the resulting off-target cytotoxicities have been reported. Recent in vitro and in vivo studies using magnetic nanocomposites (MNCs) for magnetothermal chemotherapy may potentially improve the therapeutic outcome by increasing the target selectivity. In this review, magnetic hyperthermia therapy and magnetic targeting using drug-loaded MNCs are revisited, focusing on magnetism, the fabrication and structures of magnetic nanoparticles, surface modifications, biocompatible coating, shape, size, and other important physicochemical properties of MNCs, along with the parameters of the hyperthermia therapy and external magnetic field. Due to the limited drug-loading capacity and low biocompatibility, the use of magnetic nanoparticles (MNPs) as drug delivery system has lost traction. In contrast, MNCs show higher biocompatibility, multifunctional physicochemical properties, high drug encapsulation, and multi-stages of controlled release for localized synergistic chemo-thermotherapy. Further, combining various forms of magnetic cores and pH-sensitive coating agents can generate a more robust pH, magneto, and thermo-responsive drug delivery system. Thus, MNCs are ideal candidate as smart and remotely guided drug delivery system due to a) their magneto effects and guide-ability by the external magnetic fields, b) on-demand drug release performance, and c) thermo-chemosensitization under an applied alternating magnetic field where the tumor is selectively incinerated without harming surrounding non-tumor tissues. Given the important effects of synthesis methods, surface modifications, and coating of MNCs on their anticancer properties, we reviewed the most recent studies on magnetic hyperthermia, targeted drug delivery systems in cancer therapy, and magnetothermal chemotherapy to provide insights on the current development of MNC-based anticancer nanocarrier.

2021-07-01·Cancer Research

Abstract 1150: CARG-2020 artificial oncolytic virus delivering three immune-modulators prevents tumor recurrence in a syngeneic model of ovarian cancer

作者: Almassian, Bijan ; Fox, Alexandra ; Alvero, Ayesha B. ; Mor, Gil ; Madina, Bhaskara ; Yarovinsky, Timur ; Nakaar, Valerian ; Krady, Marie

AbstractBackground: Ovarian cancer is the most lethal of all gynecologic malignancies with a grim 5-year survival rate of ~47%. Mortality occurs in the setting of recurrent disease wherein the co-presentation of chemoresistance and carcinomatosis limits the value of standard of care. It is therefore imperative to develop approaches that can prevent recurrent ovarian cancer. Oncolytic viruses are genetically modified replication competent viruses that can selectively infect cancer cells to induce cell lysis and death. This approach has proven to be clinically safe making it a promising approach to complement standard of care. The objective of this study is to evaluate the efficacy of CARG-2020, a virus-like vesicles (VLV) delivering three immune-modulators including IL-12, IL-17 antagonist and shRNA-PD-L1 in preventing recurrent disease in a syngeneic mouse model of recurrent ovarian cancer.Materials and Methods: In vitro: Triple knockout (TKO; p53LSL-R172H/Dicerflox/flox/Ptenflox/flox) mouse ovarian cancer cells were seeded in 96-well plates and treated with different doses of CARG-2020. Cell death was determined using the Incucyte imaging system. In vivo: TKO ovarian cancer cells stably expressing the mCherry fluorescent protein were injected i.p. in C57bl/6 mice (day 0) to mimic the establishment of recurrent disease. Treatment commenced on day 3 with the treatment group receiving three doses of 1x10^8 PFU of CARG-2020 given every other day (n=5). Control group received PBS (n=5). Both treatments were given i.p. Tumor growth was monitored by live imaging using mCherry fluorescence ROI area. Progression-free survival (PFS) was defined as the day ROI area reached 2,000.Results: CARG-2020 (1x10^5 PFU) demonstrated cytolytic effect in vitro and induced 100% cell death within 24h. In vivo, CARG-2020 induced significant decrease in i.p. tumor growth (p = 0.0128) compared to PBS control. Treatment with CARG-2020 completely delayed the establishment of recurrent disease (PFS, p = 0.0003). Whereas PBS control group demonstrated median PFS of 20 days, mice in the CARG-2020 group remained disease-free until day 60.Conclusion: CARG-2020 is able to prevent the establishment of recurrent disease in a syngeneic mouse model of recurrent ovarian cancer. Our results provide rationale for the further development of this platform as a therapeutic modality for ovarian cancer patients.Citation Format: Ayesha B. Alvero, Alexandra Fox, Bhaskara Madina, Valerian Nakaar, Timur Yarovinsky, Marie Krady, Bijan Almassian, Gil Mor. CARG-2020 artificial oncolytic virus delivering three immune-modulators prevents tumor recurrence in a syngeneic model of ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1150.

100 项与 CaroGen Corp. 相关的药物交易

登录后查看更多信息

100 项与 CaroGen Corp. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

3

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

CARG-2020 ( PDL1 )	乳腺癌更多	临床前
CARG-201	乙型肝炎更多	临床前
VLV based Vaccine(CaroGen)	乳腺癌更多	临床前
ADIVO/OC	卵巢癌更多	终止
ADIVO/CoV-2	新型冠状病毒感染更多	终止